P/E at 18.81 vs Industry's 31.39: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount to Industry P/E

Dr Reddys Laboratories Ltd trades at a P/E of 18.81, markedly below the Pharmaceuticals & Biotechnology industry average of 31.39. This 40% discount suggests the market is pricing in either lower growth expectations or higher risk relative to peers. Such a valuation gap is notable in a large-cap stock with a market capitalisation exceeding ₹1,06,669 crores. The sector’s elevated P/E reflects optimism about innovation and pipeline prospects, but Dr Reddys Laboratories Ltd appears to be viewed more conservatively — previously rated Hold, what is Dr Reddys Laboratories Ltd’s current rating? The valuation discount could also be a function of recent earnings volatility or competitive pressures within the sector.

Performance Across Timeframes: Mixed Momentum

Examining returns reveals a divergence between short and longer-term momentum. Over the past year, Dr Reddys Laboratories Ltd has delivered a 10.90% gain, outperforming the Sensex’s 2.98% decline. This outperformance extends to the three-year horizon, with a 38.27% return versus the Sensex’s 25.04%. However, the five-year and ten-year returns tell a different story, with the stock lagging the Sensex by 8.16% and 77.47% respectively, indicating a longer-term underperformance trend.

In the short term, the stock’s performance is more subdued. The three-month return of 1.95% modestly outpaces the Sensex’s 13.41% decline, but the one-month return of -0.71% contrasts with a sharper sector fall of 9.26%. The one-week return of -1.84% is slightly better than the Sensex’s -2.01%, while the day’s gain of 1.86% trails the Sensex’s 2.52%. This pattern suggests recent volatility and a possible pause in momentum — is this a recovery or a dead-cat bounce? The year-to-date return of 0.55% versus the Sensex’s -13.44% further highlights the stock’s relative resilience in a challenging market environment.

Moving Average Configuration: Mixed Technical Signals

The technical picture for Dr Reddys Laboratories Ltd is characterised by a nuanced moving average (MA) configuration. The stock currently trades above its 50-day, 100-day, and 200-day moving averages, signalling strength over medium and long-term horizons. However, it remains below the 5-day and 20-day moving averages, indicating short-term weakness or consolidation. This pattern often reflects a recent pullback within an overall uptrend or a pause before a potential breakout.

Such a configuration suggests that while the stock has demonstrated resilience over the past several months, recent trading sessions have seen some profit-taking or hesitation. The stock’s intraday high of ₹1280.45 on the day of reporting, a 2.06% increase, contrasts with a slight underperformance relative to the sector’s day gain, underscoring this mixed momentum. The stock’s recovery after two consecutive days of decline further emphasises this tentative technical stance — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Performance Context

The Pharmaceuticals & Biotechnology sector has experienced a varied performance landscape recently. While the sector’s average P/E remains elevated at 31.39, reflecting investor optimism, the sector’s short-term returns have been under pressure. The Sensex’s 13.41% decline over three months and 9.26% fall over one month highlight the challenges faced by the broader market, including regulatory scrutiny and pricing pressures.

Within this context, Dr Reddys Laboratories Ltd has shown relative resilience, outperforming the sector and Sensex across multiple timeframes. This outperformance is notable given the stock’s large-cap status and the sector’s mixed results, where some companies have posted gains while others have struggled. The stock’s ability to maintain a valuation discount while delivering positive returns suggests a complex interplay of market sentiment and company fundamentals.

Rating Reassessment and Historical Context

Previously rated Hold by MarketsMOJO, Dr Reddys Laboratories Ltd had its rating reassessed on 23 Mar 2026. The current Mojo Score stands at 48.0, with a Mojo Grade of Sell. This shift in rating reflects a reassessment of the stock’s valuation and performance metrics, particularly in light of its P/E discount and mixed momentum signals. The rating update invites investors to reconsider the stock’s positioning within their portfolios — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Conclusion: A Complex Valuation and Momentum Landscape

The data for Dr Reddys Laboratories Ltd paints a picture of a large-cap pharmaceutical stock trading at a significant valuation discount to its industry peers. Its one-year and three-month returns show relative strength, while short-term technical indicators suggest a cautious stance among traders. The moving average configuration points to a stock that is recovering from recent weakness but has yet to regain short-term momentum fully.

Sector headwinds and regulatory challenges continue to influence the broader Pharmaceuticals & Biotechnology space, making valuation and performance analysis critical for investors. The recent rating reassessment from Hold to Sell by MarketsMOJO underscores the need to weigh these factors carefully — what is the current rating for Dr Reddys Laboratories Ltd?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today